Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy by Dockum, W.G. van et al.
Visser and Albert C. van Rossum
Olga Bondarenko, Marco J.W. Götte, Jos W.R. Twisk, Mark B.M. Hofman, Cees A. 
Willem G. van Dockum, Aernout M. Beek, Folkert J. ten Cate, Jurrien M. ten Berg,
Septal Ablation in Hypertrophic Obstructive Cardiomyopathy
Early Onset and Progression of Left Ventricular Remodeling After Alcohol
ISSN: 1524-4539 
Copyright © 2005 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online
72514
Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX
doi: 10.1161/01.CIR.0000165084.28065.01
2005, 111:2503-2508: originally published online May 2, 2005Circulation 
http://circ.ahajournals.org/content/111/19/2503
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
http://www.lww.com/reprints
Reprints: Information about reprints can be found online at 
  
journalpermissions@lww.com
410-528-8550. E-mail: 
Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
http://circ.ahajournals.org//subscriptions/
Subscriptions: Information about subscribing to Circulation is online at 
 at Vrije on July 28, 2011http://circ.ahajournals.org/Downloaded from 
Early Onset and Progression of Left Ventricular
Remodeling After Alcohol Septal Ablation in Hypertrophic
Obstructive Cardiomyopathy
Willem G. van Dockum, MD; Aernout M. Beek, MD; Folkert J. ten Cate, MD, PhD;
Jurrien M. ten Berg, MD, PhD; Olga Bondarenko, MD; Marco J.W. Götte, MD, PhD; Jos W.R. Twisk, PhD;
Mark B.M. Hofman, PhD; Cees A. Visser, MD, PhD; Albert C. van Rossum, MD, PhD
Background—Alcohol septal ablation (ASA) reduces left ventricular outflow tract (LVOT) pressure gradient in patients
with hypertrophic obstructive cardiomyopathy (HOCM), which leads to left ventricular remodeling. We sought to
describe the early to midterm changes and modulating factors of the remodeling process using cardiac MRI (CMR).
Methods and Results—CMR was performed at baseline and 1 and 6 months after ASA in 29 patients with HOCM (age
5216 years). Contrast-enhanced CMR showed no infarct-related hyperenhancement outside the target septal area.
Septal mass decreased from 7523 g at baseline to 6822 and 5819 g (P0.001) at 1- and 6-month follow-up,
respectively. Remote, nonseptal mass decreased from 14141 to 13240 and 11127 g (P0.001), respectively.
Analysis of temporal trends revealed that septal mass reduction was positively associated with contrast-enhanced infarct
size and transmural or left-sided septal infarct location at both 1 and 6 months. Remote mass reduction was associated
with infarct location at 6 months but not with contrast-enhanced infarct size. By linear regression analysis, percentage
remote mass reduction correlated significantly with LVOT gradient reduction at 6-month follow-up (P0.03).
Conclusions—Left ventricular remodeling after ASA occurs early and progresses on midterm follow-up, modulated by
CMR infarct size and location. Remote mass reduction is associated with infarct location and correlates with reduction
of the LVOT pressure gradient. Thus, myocardial hypertrophy in HOCM is, at least in part, afterload dependent and
reversible and is not exclusively caused by the genetic disorder. (Circulation. 2005;111:2503-2508.)
Key Words: hypertrophy  cardiomyopathy  ablation  remodeling  magnetic resonance imaging
In symptomatic patients with hypertrophic obstructive car-diomyopathy (HOCM), alcohol septal ablation (ASA) has
been shown to be an attractive alternative to surgical myec-
tomy.1–4 During the ASA procedure, a chemical infarction is
artificially induced, which results in regional thinning of the
interventricular septum, an increase in outflow tract diameter,
and a decrease in pressure gradient and subsequent symptom-
atic improvement.5,6 Some studies have also shown a regres-
sion of remote hypertrophy after successful reduction of the
outflow tract gradient.7–11 This may contribute to symptom
relief by improving diastolic function.12 However, reports
have not been conclusive, which may be explained in part by
the fact that echocardiographic calculations of left ventricular
(LV) mass use geometric assumptions that may not be valid
in patients with large differences in regional wall thickness.
Cardiac MRI (CMR) allows direct mass calculations and has
shown high reproducibility in detecting small changes in
global and regional mass.13,14 Using CMR, we recently
showed significant reductions in septal and nonseptal, remote
myocardial mass 1 month after septal ablation.15 A progres-
sive reduction in remote mass beyond the early phase would
provide strong evidence for the suggested relation between
relief of outflow tract gradient and LV remodeling. The aim
of this study was therefore to evaluate changes and potential
modulating factors of these changes in LV remodeling during
the first 6 months after ASA.
Methods
Patients
The study protocol was approved by the Committee on Research
Involving Human Subjects and the Medical Ethics Committee of the
VU University Medical Center, Amsterdam. Consecutive patients
with HOCM scheduled to undergo ASA in 1 of 2 referral centers in
the Netherlands were candidates for the study. The indication for
ASA was based on a significant LV outflow tract (LVOT) gradient,
documented by Doppler echocardiography (50 mm Hg), and New
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York Heart Association NYHA functional class II, III, or IV despite
medical treatment. All patients had basal septal hypertrophy with
systolic anterior motion of the anterior mitral valve leaflet. The ASA
procedure was described previously.15 Exclusion criteria were any
absolute or relative contraindication to CMR (eg, pacemaker or
claustrophobia), atrial fibrillation, or failure to give informed con-
sent. Thirty-three consecutive patients were enrolled initially. Four
patients were excluded from the final analysis: 3 required pacemaker
implantation because of development of complete atrioventricular
block after ASA, and 1 declined to return for the follow-up
examinations. The remaining 29 patients formed the final study
group. Four patients had resting gradients 50 mm Hg, which
increased to 50 mm Hg with provocation with the Valsalva
maneuver. A successful ablation procedure was defined as 50%
gradient reduction at 1 month compared with baseline. The baseline
characteristics of these patients are listed in Table 1.
Cardiac MRI
CMR was performed at baseline and 1 and 6 months after ASA with
a 1.5-T clinical scanner (Sonata, Siemens) and a 4-element, phased-
array body radiofrequency receiver coil. All images were acquired
with ECG gating and during repeated breath holds of 10 to 15
seconds, depending on heart rate. Cine images were acquired with a
segmented steady state, free precession, gradient-echo sequence in 3
long-axis views (2-, 3-, and 4-chamber view) and in multiple
short-axis views every 10 mm, which covered the entire LV from
base to apex. At 1-month follow-up, contrast-enhanced CMR was
also performed. Contrast-enhanced images were acquired 15 to 20
minutes after intravenous administration of 0.2 mmol/kg
gadolinium-DTPA in the same views as in cine CMR with a 2D,
segmented, inversion-recovery, prepared gradient-echo
sequence.16–18
CMR Analysis
Analysis of Contrast-Enhanced Images
Contrast-to-noise ratio of the hyperenhanced area versus a remote
nonenhanced myocardial area was measured on the short-axis slice
that demonstrated the largest area of hyperenhancement. Contrast-
to-noise ratio was calculated with regions of interest and was defined
as (SIhyperenhancedSIremote)/noise, where SI is signal intensity and noise
is expressed as the SI standard deviation in a background region of
interest.
Infarct size after ASA was measured by manual tracing of the
hyperenhanced area, which was defined as the area within the septal
myocardium with pixel SI values 4 SD of remote, nonenhanced
myocardium.15 Central dark zones within the area of hyperenhance-
ment were included. The center of the infarct area was defined as the
center of the hyperenhanced area on the short-axis image with the
largest area of hyperenhancement.
Analysis of Cine Images
For all patients, CMR scans were placed in random order after the
identity markers were removed. Interventricular septal (IVS) wall
thickness at the infarct site was measured at end diastole in the
short-axis view that included the center of the infarct. The slice
position and measurement site was copied from the contrast image to
the corresponding cine view of the 1-month study and subsequently
to the baseline and 6-month studies. Wall thickness at the septal,
anterior, lateral, and inferior wall and LV end-diastolic and end-sys-
tolic dimensions were all determined in the midventricular short-axis
view (level of papillary muscles). Left atrial dimension was mea-
sured at end systole in the 3- and 4-chamber views. LV end-diastolic
volume, end-systolic volume, ejection fraction, and total and septal
myocardial mass were quantified with the MASS software package
(MEDIS). Endocardial and epicardial borders were outlined manu-
ally in end-diastolic and end-systolic frames of all short-axis slices.
Papillary muscles were included in the assessment of LV mass. The
IVS was defined as the myocardium between the anterior and
posterior junctions of the right ventricle to the LV. Remote,
nonseptal LV mass was calculated as LV total massIVS mass.
Statistical Analysis
Results are expressed as meanSD. Longitudinal data analysis was
performed with generalized estimating equations (GEEs) for serial
measurements to evaluate the changes in LV wall thickness, LV
end-diastolic and end-systolic dimensions, left atrial dimension, LV
volumes, and LV myocardial mass after ASA.19 In the GEE
modeling, time was added as a categorical variable indicated by
dummies.20 In addition to the cru development over time, the
influence of certain modulating variables (eg, age, LVOT pressure
gradient before ablation, infarct location, and infarct size measured
by contrast-enhanced CMR and cardiac enzyme release) was inves-
tigated. First, the particular variables were added one at the time to
the GEE models to investigate whether the intercept of the develop-
ment was influenced, ie, whether the variables were stand-alone
factors that affected the trend. Second, the interactions between the
particular variables and time (ie, the 2-time dummy variables) were
added to the models to investigate whether the development over
time was different for the different levels of the modulating vari-
ables. All GEE analyses were performed with STATA version 7.
Linear regression analysis was used to analyze the relationship
between LVOT gradient reduction and remote mass reduction.
Reproducibility measurements of the acquisition and the intraob-
server and interobserver variability (expressed as intraclass coeffi-
cients) were calculated in 10 consecutive patients by 2 independent
observers. All statistical analyses were performed with SPSS version
11.0, and significance was set at a probability value 0.05.
Results
Mean age was 5216 years (range 18 to 71 years), and 13 of
the 29 patients were female. All but one were receiving 1 or
more drugs (-blocker [n19], calcium channel blockers
[n16], or antiarrhythmic drugs [n5]). After ASA, the use
of medications was reduced markedly (only 10 patients were
still taking -blockers, and 5 of these were receiving half the
dosage compared with baseline; only 7 patients were still
taking calcium channel blockers). During the ablation proce-
dure, ethanol was injected in 1 septal artery in 27 patients, and
2 septal arteries were ablated in 2 patients. The mean volume
of ethanol injected per artery was 3.21.5 mL. Before ASA,
25 patients had a resting LVOT pressure gradient
50 mm Hg (8719 mm Hg; range 52 to 120 mm Hg), and
4 had provocable gradients (6824 mm Hg; range 50 to
100 mm Hg). The mean dynamic pressure gradient decreased
from 8521 to 2127 mm Hg at 1 month after septal
ablation therapy (P0.01). Four patients had unsuccessful
gradient reduction. NYHA functional class improved signif-
icantly; at baseline, 3 patients were in NYHA class II, 24
were in class III, and 2 were in class IV. At 1-month
follow-up, 13 patients were without symptoms, 12 were in
NYHA class II, and 4 were in class III. Three patients were
lost for the 6-month follow-up examination: 1 underwent a
redo procedure for recurrent symptoms and significant resting
TABLE 1. Patient Characteristics (n29)
Age, y (men/women) 5216 (16/13)
NYHA functional class (II/III/IV), n 3.00.4 (3/24/2)
Dyspnea/angina/syncope 29/13/5
Medication
-Blockers/calcium antagonists 19/16
Antiarrhythmic drugs/diuretics 5/2
Values are expressed as meanSD (n) or number of patients.
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gradient, 1 underwent pacemaker implantation due to late
development of complete atrioventricular block after ASA,
and 1 had a car accident with multiple bone fractures that
made the CMR examination impossible.
Infarct Size and Location
The mean peak creatine kinase (CK) and CK-MB release
were 1612707 U (range 381 to 3366 U) and 21795 U
(range 55 to 371 U), respectively. At 1-month follow-up, a
clearly demarcated area of hyperenhancement was visualized
in the basal part of the IVS in all patients (Figure 1). Mean
myocardial infarct size was 209 g (range 5 to 42 g) and
involved 115% of the total LV mass and 3216% of the
septal myocardial mass at 1 month after ASA. As we
previously reported, the infarct extended transmurally
throughout the IVS in 20 patients, was located exclusively on
the LV side of the IVS in 2 patients, and was located
exclusively on the right ventricular side of the IVS in 7
patients. No patient had evidence of infarct-related hyperen-
hancement outside the target area.
Changes in LV Wall Thickness and Dimensions
End-diastolic IVS thickness measured at the infarct site
decreased from 2.10.4 cm at baseline to 1.40.4 cm at 1
month and 1.00.4 cm at 6 months. Anterior, lateral, and
inferior wall thickness at the mid-LV level also progressively
decreased at 1 and 6 months after ASA. Whereas LV
end-diastolic dimensions remained unchanged, end-systolic
dimensions increased during follow-up. Furthermore, left
atrial end-systolic dimensions in both the 3- and 4-chamber
views decreased significantly (Table 2).
Longitudinal data analysis of the influence of modulating
variables revealed that none influenced the intercept of the
development. However, the following modulators affected de-
velopment over time of the 2D parameters: (1) A larger decrease
in IVS wall thickness was associated with a larger contrast-
enhanced infarct size (P0.01 at 1 and 6 months, respectively),
higher levels of CK (P0.01 and P0.06, respectively) and
CK-MB release (P0.03 and P0.08, respectively), and trans-
mural or left-sided septal infarct location (P0.01 at 1 and 6
months, respectively). (2) The decrease in remote myocardial
wall thickness was not influenced significantly by any of the
variables. (3) A larger increase in LV end-systolic dimension
was associated with larger contrast-enhanced infarct size at
1-month follow-up only (P0.04). (4) A larger decrease in left
atrial dimension was associated with larger contrast-enhanced
infarct size (P0.03) and with transmural or left-sided septal
infarct location (P0.03).
Changes in LV Mass, Volumes, and Function
Changes in 3D LV parameters are summarized in Table 3. LV
end-diastolic volumes remained unchanged at follow-up,
whereas end-systolic volumes increased significantly. Conse-
quently, there was a small decrease in LV ejection fraction at
Figure 1. Example of cine and contrast-
enhanced magnetic resonance images in
patient with HOCM at baseline and at 1
and 6 months after ASA. Distribution of
hypertrophy is demonstrated in end-dia-
stolic basal short-axis (SA) view and 3-
and 4-chamber views. Thinning of basal
interventricular septum is evident, as well
as widening of LVOT. Second row dem-
onstrates hyperenhancement in basal
septum, which reflects ethanol-induced
myocardial infarction 1 month after ASA.
FU indicates follow-up; chview, chamber
view.
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1 and 6 months. Total LV myocardial mass decreased from
21662 g at baseline to 20060 g (8%) at 1 month and
17045 g (21%) at 6 months. Septal myocardial mass
decreased from 7523 to 6822 g (10%) at 1 month and
to 5819 g (23%) at 6 months. Nonseptal mass decreased
from 14141 g at baseline to 13240 g (6%) at 1 month
and to 11127 g (21%) at 6 months’ follow-up. The
relative reduction of septal and nonseptal myocardial mass is
shown in Figure 2.
Also with respect to these 3D parameters, the intercept of
the development was not influenced by the modulating
variables. Time-dependent trends were as follows: (1) A
larger decrease of septal mass was associated with larger
contrast-enhanced infarct size (P0.01 at 1 and 6 months,
respectively), higher levels of CK (P0.05 at 1 month and
P0.01 at 6 months) and CK-MB (P0.17 at 1 month and
P0.03 at 6 months), and transmural or left-sided septal
location (P0.01 at 1 and 6 months, respectively). (2) A
larger decrease of remote mass was associated with transmu-
ral or left-sided septal infarct location (P0.12 at 1 month
and P0.01 at 6 months) but not with contrast-enhanced
septal infarct size.
Reproducibility measurements of image acquisition and
intraobserver and interobserver variability were performed in
10 consecutive patients by 2 independent observers. Intra-
class coefficients of reproducibility and of intraobserver and
interobserver variability ranged between 0.98 and 0.99 for
end-diastolic volume, end-systolic volume, ejection fraction,
and myocardial mass, respectively.
Correlation Between Regional Mass Reduction and
Gradient Reduction
Linear regression analysis showed a significant association
between percent reduction of remote mass and LVOT pres-
sure gradient reduction at 6-month follow-up (r0.44,
P0.03; Figure 3). No correlation was found between per-
cent reduction of septal mass and LVOT gradient reduction
(r0.31, P0.12).
Discussion
Quantitative analysis without geometric assumptions re-
vealed a significant early and progressive LV remodeling
with reduction in septal and remote myocardial mass through-
out the 6-month follow-up period. Whereas diastolic volumes
remained unchanged, systolic volumes increased, and left
atrial dimensions decreased. CMR-derived infarct size and
location were found to modulate the early temporal changes
of the parameters that reflect the LV remodeling process.
Whereas reduction in septal mass was associated with infarct
size and location, reduction in remote mass was associated
with infarct location and not with infarct size and correlated
significantly with reduction of the LVOT gradient. Because
absence of hyperenhancement outside the target septal area
excluded alcohol-induced injury on remote myocardium,
remote myocardial remodeling may be attributed to the
reduction in outflow tract gradient and the concomitant
decrease in LV wall stress. The association with infarct
location became apparent at 6 months only, which reflects a
TABLE 2. Cardiac Dimensions at Baseline and After ASA
Baseline 1-Month Follow-Up 6-Month Follow-Up
IVS thickness at infarct site, mm 20.74.1 14.53.9* 10.23.7*
Wall thickness at mid-LV level, mm
Septal wall 17.55.3 16.24.8* 14.75.0*
Anterior wall 9.63.0 9.22.9* 8.63.1*
Lateral wall 8.21.7 7.91.7* 7.11.6*
Inferior wall 10.22.9 9.72.8* 9.32.8*
LV end-diastolic diameter, mm 47.85.3 47.85.8 47.55.7
LV end-systolic diameter, mm 25.84.0 29.36.0* 28.85.7*
LA end-systolic diameter (3-chamber view), mm 50.96.5 46.26.8* 45.77.2*
LA end-systolic diameter (4-chamber view), mm 59.27.4 54.56.3* 52.45.8*
Values are expressed as meanSD.
*P0.01 vs baseline.
TABLE 3. LV Volumes and Mass at Baseline and After ASA
Baseline 1-Month Follow-Up 6-Month Follow-Up
LV end-diastolic volume, mL 17042 16741 16939
LV end-systolic volume, mL 5416 5718* 5917†
Stroke volume, mL 11629 11025* 11025
LV ejection fraction, % 695 675† 664†
Total LV mass, g 21662 20060† 17045†
Septal mass, g 7523 6822† 5819†
Nonseptal mass, g 14141 13240† 11127†
Values are expressed as meanSD.
*P0.05 vs baseline; †P0.01 vs baseline.
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more gradual process of remodeling than in the IVS, where
the association is immediately apparent at 1 month and
remains at 6 months because of the directly inflicted infarct.
Also, the reversibility of the remote myocardial mass implies
that hypertrophy in HOCM is not caused exclusively by the
genetic disorder but is induced, at least in part, secondary to
the dynamic obstruction of the outflow tract.
Changes in Septal and Remote Myocardial Mass
After ASA
The genetic disorder in HOCM leads to a primary molecular
abnormality. Expression of mutant sarcomeric proteins (con-
tractile units) leads to a decrease in generation of force, which
results in impaired cardiac myocyte contractility and in-
creased cardiac myocyte stress.21 In the subset of patients
with LVOT obstruction, increased LV pressure and wall
stress induce secondary hypertrophy that may be (partly)
reversible after elimination of the LVOT obstruction.9,22
Previous echocardiographic studies have shown ambiguous
results with respect to reduction of LV posterior wall thick-
ness.7–11,23–26 Tomographic techniques such as electron-beam
computed tomography and CMR may be more accurate and
reproducible than echocardiographic measurements and LV
mass calculations. Electron-beam computed tomography
showed septal mass reduction 1 week after ASA and found
reduced remote mass at 4 to 6 months of follow-up.11 The
results of the present study using CMR are in line with these
observations and additionally revealed factors associated with
the remodeling process over time. Not surprisingly, septal
wall thickness and septal mass demonstrated immediate and
progressive reduction associated with the alcohol-induced
infarct size and location at 1 and 6 months. Reduction of
remote wall thickness, however, although significant at 1 and
6 months, was not associated with infarct size and location at
any time, whereas reduction of the mass did show an
association with infarct location at 6 months. 2D measure-
ments of wall thickness performed regionally probably are
less precise than 3D mass calculation of the entire remote
myocardium in revealing the association with the gradual
process of remote remodeling over time.
The early onset of regression of remote hypertrophy may
be explained by an immediate reduction in the expression of
cardiac growth factors. Nagueh et al22 found decreased
expression of myocardial tumor necrosis factor- in patients
with HOCM 6 weeks after relief of the LVOT obstruction by
ASA. The decreased cardiac levels of tumor necrosis factor-
were accompanied by a reduction in myocyte size and in the
amount of interstitial collagen.
The causative relation between regression of remote hy-
pertrophy and reduction in outflow tract gradient is supported
by the correlation that reached statistical significance at
6-month follow-up. The relation between septal mass reduc-
tion and outflow tract gradient reduction was not significant.
Septal mass reduction is the result of the chemically induced
infarction and subsequent scar formation, a direct process that
is not secondary to the reduction in LVOT gradient. This is
supported by the positive time-dependent interactions of
septal mass reduction with contrast-enhanced infarct size: a
larger reduction in septal myocardial mass was associated
with larger contrast-enhanced infarcts. In contrast, the change
in remote mass was not associated with contrast-enhanced
infarct size but only with transmural or left-sided septal
location.
Changes in Dimensions and Volumes After ASA
Previous studies have generally found significant increases in
both end-systolic and end-diastolic dimensions.9,27 We found
a significant increase in end-systolic dimension and a small
but significant increase in LV end-systolic volume at 6-month
follow-up. These changes may be explained by septal thin-
ning and reduced thickening as a result of the ethanol-induced
infarction. LV end-diastolic dimension and volume remained
unchanged at both follow-up CMR scans. As a result, there
was a small decrease in LV ejection fraction at 6 months.
Left atrial dimensions decreased after ASA, with larger
decreases being associated with larger contrast-enhanced
infarcts. The decrease is likely to reflect the effect of the ASA
procedure on improving diastolic function.
A general limitation of the present study is the difficulty in
obtaining blinded measurements, because effects of treatment
Figure 2. Percent changes in septal and remote LV myocardial
mass after ASA at 1- and 6-month follow-up.
Figure 3. Correlation between reduction in remote myocardial
mass and LVOT gradient reduction at 6-month follow-up.
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by ASA are often clearly visible for the experienced CMR
observer, which thus introduces observer bias in judgment of
postablation wall thickness. In the present study, we did not
measure the increase in LVOT area, which has been shown to
have a close relationship with the decrease in septal wall
thickness.28 These measurements, however, require imaging
of the LVOT in multiple orientations, with addition of flow
quantification acquisitions, which is time consuming. In our
imaging protocol, we gave priority to the addition of acqui-
sitions of delayed imaging after gadolinium. Furthermore,
only left atrial dimensions were measured, which are likely to
be less accurate than volume determinations. However, our
primary aim was not to measure the effects of ASA on left
atrial volumes, and consequently, the CMR protocol did not
include full coverage for measuring left atrial volume. We
merely sought to provide circumstantial evidence in support
of improvement of diastolic function. Moreover, dimensions
may be more meaningful to clinicians than left atrial volumes.
In summary, we used CMR to evaluate LV remodeling
after ASA in symptomatic patients with HOCM. LV remod-
eling occurred early and progressed on midterm follow-up,
modulated by infarct size and location. Regression of non-
septal, remote myocardial mass was significantly associated
with infarct location and correlated with the reduction in
LVOT pressure gradient at 6-month follow-up. Our findings
support the theory that myocardial hypertrophy in patients
with HOCM is, at least in part, afterload dependent and
reversible and thus is not caused exclusively by the genetic
disorder.
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